IMPACT Therapeutics (IMPACT) released updated clinical results for three pipeline assets—senaparib (IMP4297), IMP1734 (EIK1003) and IMP1707 (EIK1004)—during poster sessions at the European Society for Medical Oncology (ESMO) Congress in Madrid (23–27 October 2026). The data underscore continued progress across the company’s synthetic-lethality oncology franchise.
Senaparib (IMP4297): In the Phase 3 FLAMES study, first-line maintenance therapy with senaparib delivered a median progression-free survival (PFS) of 38.70 months versus 13.60 months for placebo (hazard ratio = 0.47; 95% CI: 0.36–0.62; p<0.0001) after a 48.5-month median follow-up. Benefit was consistent across genomic subgroups: BRCA-mutated patients achieved a median PFS of 49.80 months compared with 15.60 months for placebo (HR = 0.41), while BRCA-wild-type patients reached 33.30 months versus 12.90 months (HR = 0.49). The therapy is already approved in China (January 2025) for first-line maintenance in advanced ovarian cancer and is under EMA review, with a decision expected in 2H 2026.
IMP1734 (EIK1003): Updated Phase 1/2 findings highlight a favorable hematologic safety profile and promising activity. • Combination with abiraterone in metastatic prostate cancer (mPC): Grade ≥3 anemia was reported in 15% of patients; objective response rate (ORR) reached 19.0% in metastatic castration-resistant prostate cancer (mCRPC) and 33.3% in metastatic castration-sensitive disease (mCSPC). Prostate-specific antigen (PSA50) responses were 26.5% in mCRPC and 60.0% in mCSPC across 39 evaluable patients. Activity extended beyond BRCA alterations to other HRR mutations such as ATM. • Monotherapy and paclitaxel combination in advanced solid tumors: As monotherapy, IMP1734 achieved an ORR of 14.3% with limited Grade ≥3 anemia (9.2%) and neutropenia (7.7%). In combination with weekly paclitaxel, the regimen produced ORRs of 29.6% in ovarian cancer and 23.1% in breast cancer, despite most patients having prior taxane or PARP inhibitor exposure. Hematologic toxicity was comparable to historical paclitaxel data, with Grade ≥3 neutropenia in 49.2% and anemia in 18.0% of participants.
IMP1707 (EIK1004): The first-in-human Phase 1/2 study of this CNS-penetrant PARP1-selective inhibitor reported minimal high-grade hematologic toxicity (Grade ≥3 anemia and neutropenia each at 1.5%; no severe thrombocytopenia). Early signs of efficacy included tumor shrinkage in ovarian, prostate and breast cancers; two of four evaluable prostate cancer patients achieved confirmed partial responses, and a complete response was observed in a breast cancer patient at a 20 mg dose with treatment ongoing beyond 10 months.
Corporate context: IMPACT, listed on the Hong Kong Stock Exchange in May 2026, commercialised senaparib in China in January 2025 and secured national reimbursement in January 2026. Alongside its marketed PARP1/2 inhibitor, the company is advancing a pipeline that includes PARP1-selective, ATR and WEE1 inhibitors as part of its broader synthetic-lethality strategy.
Management outlook: Chief Executive Officer Dr. Sui Xiong Cai stated that the new data validate senaparib’s role as a first-line maintenance option for all advanced ovarian cancer patients and support the clinical versatility of the next-generation PARP1-selective candidates. IMPACT plans to maintain momentum in global development and expand collaborations with partner Eikon Therapeutics to address unmet cancer treatment needs.
Comments